M Bakri Hammami

Dr. M Bakri Hammami

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2017 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
MHM Bakri Hammami
M Bakri Hammami
EMEman Qasem Mohammed
Eman Qasem Mohammed
AHAnas Mohammad Hashem
Anas Mohammad Hashem
MAMina Amer Al-Khafaji
Mina Amer Al-Khafaji
FAFatima Alqahtani
Fatima Alqahtani
NDNihar Ranjan Dash
Nihar Ranjan Dash

14 December 2021 in Neurology
Verified
Journal Article
Open access
PDF file
SSShahar Shelly
Shahar Shelly
CKChristopher J. Klein
Christopher J. Klein
PDP. James B. Dyck
P. James B. Dyck
PPPritikanta Paul
Pritikanta Paul
MMMichelle L. Mauermann
Michelle L. Mauermann
DDDivyanshu Dubey
Divyanshu Dubey
Background and Objective Multiple studies highlighting the diagnostic utility of neurofascin-155 (NF155)–immunoglobulin G4 (IgG4) in chronic demyelinating inflammatory polyradiculoneuropathy (CIDP) have been published. However, few studies comprehensively address the long-term outcomes or clinical utility of NF155–immunoglobulin M (IgM) or NF155–immunoglobulin G (IgG) in the absence of NF155-IgG4. We evaluated phenotypic and histopathologic specificity and differences in outcomes between these NF155 antibody isotypes or IgG subclasses. We also compare NF155-IgG4-seropositive cases to other seropositive demyelinating neuropathies. Methods Neuropathy patient sera at Mayo Clinic were tested for NF155-IgG4, NF155-IgG, and NF155-IgM autoantibodies. Demographic and clinical data of all seropositive cases were reviewed. Results We identified 32 NF155 cases (25 NF155-IgG-positive [20 NF155-IgG4-positive], 7 NF155-IgM-seropositive). NF155-IgG4-seropositive patients clinically presented with distal more than proximal muscle weakness, positive sensory symptoms (prickling, asymmetric paresthesia, neuropathic pain), and gait ataxia. Cranial nerve involvement (11/20 [55%]) and papilledema (4/12 [33%]) occurred in many. Electrodiagnostic testing (EDX) demonstrated demyelinating polyradiculoneuropathy (19/20 [95%]). Autonomic involvement occurred in 45% (n = 9, median composite autonomic scoring scale score 3.5, range 1–7). Nerve biopsies from the NF155-IgG4 patients (n = 11) demonstrated grouped segmental demyelination (50%), myelin reduplication (45%), and paranodal swellings (50%). Most patients needed second- and third-line immunosuppression but had favorable long-term outcomes (n = 18). Among 14 patients with serial EDX over 2 years, all except one demonstrated improvement after treatment. NF155-IgG-positive, NF155-IgG4-negative (NF155-IgG-positive) and NF155-IgM-positive patients were phenotypically different from NF155-IgG4-seropositive patients. Sensory ataxia, neuropathic pain, cerebellar dysfunction, and root/plexus MRI abnormalities were significantly more common in NF155-IgG4-positive compared to myelin-associated glycoprotein (MAG)–IgM neuropathy. Chronic immune sensory polyradiculopathy (CISP)/CISP-plus phenotype was more common among contactin-1 neuropathies compared to NF155-IgG4-positive cases. NF155-IgG4-positive cases responded favorably to immunotherapy compared to MAG-IgM-seropositive cases with distal acquired demyelinating symmetric neuropathy (p < 0.001) and had better long-term clinical outcomes compared to contactin-1 IgG (p = 0.04). Discussion We report long-term follow-up and clinical outcome of NF155-IgG4 cases. NF155-IgG4 but not IgM or IgG cases have unique clinical–electrodiagnostic signature. We demonstrate NF155-IgG4-positive patients, unlike classical CIDP with neuropathic pain and dysautonomia common at presentation. Long-term outcomes were favorable. Classification of Evidence This study provides Class III evidence that NF155-IgG4-seropositive patients, compared to patients with typical CIDP, present with distal more than proximal muscle weakness, positive sensory symptoms, and gait ataxia.

17 December 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
CVCristina Valencia-Sanchez
Cristina Valencia-Sanchez
AKAndrew M Knight
Andrew M Knight
MHM Bakri Hammami
M Bakri Hammami
YGYong Guo
Yong Guo
JMJohn R Mills
John R Mills
DDDivyanshu Dubey
Divyanshu Dubey
Objectives To report the expanded neurological presentations and oncological associations of tripartite motif-containing protein 46 (TRIM46)-IgG seropositive patients. Methods Archived sera/cerebrospinal fluid (CSF) were evaluated by tissue-based immunofluorescence assay to identify patients with identical axon initial segment (AIS)-specific staining pattern. Phage immunoprecipitation sequencing (PhIP-Seq) was used to identify the putative autoantigen. Results IgG in serum (17) and/or CSF (16) from 25 patients yielded unique AIS-specific staining on murine central nervous system (CNS) tissue. An autoantibody specific for TRIM46 was identified by PhIP-Seq, and autoantigen specificity was confirmed by transfected COS7 cell-based assay. Clinical information was available for 22 TRIM46-IgG seropositive patients. Fifteen were female (68%). Median age was 67 years (range 25–87). Fifteen (68%) patients presented with subacute cerebellar syndrome (six isolated; nine with CNS accompaniments: encephalopathy (three), brainstem signs (two), myelopathy (two), parkinsonism (one)). Other phenotypes included limbic encephalitis (three), encephalopathy with/without seizures (two), myelopathy (two). Eighteen (82%) had cancer: neuroendocrine carcinomas (9; pancreatic (3), small-cell lung (4), oesophagus (1), endometrium (1)), adenocarcinomas (6; lung (2), ovarian (2), endometrial (1), breast (1)), sarcoma (2) and gastrointestinal tumour (1). Neurological symptoms in three followed immune checkpoint inhibitor (ICI) administration. Conclusions This study supports TRIM46-IgG being a biomarker of paraneoplastic CNS disorders and expands the neurological phenotypes, oncological and ICI-related adverse event associations.

13 June 2022 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
DDDivyanshu Dubey
Divyanshu Dubey
GBGrayson Beecher
Grayson Beecher
MHM Bakri Hammami
M Bakri Hammami
AKAndrew M. Knight
Andrew M. Knight
TLTeerin Liewluck
Teerin Liewluck
MMMargherita Milone
Margherita Milone
Immune-mediated rippling muscle disease (iRMD) is a rare myopathy characterized by abnormal muscle excitability. It is usually electrically silent, exhibiting wavelike muscle contractions (rippling) and percussion- or stretch-induced muscle mounding.1 In contrast to hereditary rippling muscle disease (hRMD), associated to date with pathogenic variants in caveolin-3 (CAV3) or, less frequently, cavin-1 (CAVIN1) genes, patients with iRMD lack a defined genetic defect.2,3 Responsiveness to immunotherapy supports an autoimmune pathogenesis. Muscle acetylcholine receptor antibody positivity with or without clinical myasthenia gravis (MG) has been reported in association with iRMD, further favoring its potential immune-mediated etiology.4-6

1 January 2019 in Avicenna Journal of Medicine
Verified
Journal Article
Open access
OAOmar Almidani
Omar Almidani
TTTala Tillawi
Tala Tillawi
ASAhmad Saqer
Ahmad Saqer
MHM Bakri Hammami
M Bakri Hammami
HTHazem Taifour
Hazem Taifour
HMHeba Mohammad
Heba Mohammad
Background: Injury is an important cause of mortality and morbidity. It is the second most common cause of death in the United Arab Emirates (UAE) for the last 15 years, claiming more than 1200 lives annually. Those numbers can be significantly reduced through first aid (FA) education and training. The aim of this study was to investigate the knowledge and attitude toward FA in the UAE. Methods: Self-administered questionnaires were distributed through nonprobability sampling method to more than 500 residents across the UAE, aged at least 30 years. Data collection was conducted between July 20, 2017, and September 20, 2017. The number of participants from each city was proportionate to the population size according to the latest available census. Results: More than half of the population (54.2%) were not sufficiently knowledgeable about basic FA. Only 33.8% took an FA course. Age of the participants, higher education, and taking FA courses significantly increased the knowledge about basic FA information. Most of the population showed positive attitude toward FA and were willing to take an FA course in the future. Conclusion: The knowledge about FA in the UAE population is limited. FA courses must be made more accessible for the population and updated at frequent intervals. More emphasis should be given to basic FA information.

20 July 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
MHM Bakri Hammami
M Bakri Hammami
SEScott D Z Eggers
Scott D Z Eggers
AMAjay Madhavan
Ajay Madhavan
MMMayra J Montalvo
Mayra J Montalvo
SPSean J Pittock
Sean J Pittock
DDDivyanshu Dubey
Divyanshu Dubey
Objective Cochleovestibulopathy is a distinguishable paraneoplastic phenotype. In this study, we evaluate clinical presentation, serological/cancer associations and outcomes of paraneoplastic cochleovestibulopathy. Methods Retrospective chart review of patients with hearing impairment and/or vestibulopathy who underwent serological evaluations for paraneoplastic antibodies between January 2007 and February 2021 was performed. Results Twenty-six patients were identified (men, n=23; median age, 45 years, range: 28–70). Biomarkers detected included: KLHL11-IgG‌ ‌(n=20,‌ ‌77% (coexisting LUZP4-IgG, n=8)),‌ ‌‌ANNA1-IgG‌ ‌ ‌(n=3,‌ ‌12%),‌ ‌amphiphysin-IgG‌‌ ‌(n=2,‌ ‌8%)‌ ‌and‌ ‌LUZP4-IgG‌‌ ‌(n=1,‌ ‌4%). Most common neoplastic association was ‌testicular‌/‌extra-testicular‌ ‌seminoma‌ ‌ (n=13,‌ ‌50%).‌‌ Hearing‌ impairment (bilateral, 62%) was ‌present‌ ‌in‌ ‌all‌ ‌patients.‌ ‌Fifteen patients (58%) had cochleovestibular dysfunction as their initial presentation before rhombencephalitis/encephalomyelitis manifestations (hearing loss, four; acute vertigo, eight; both, three). ‌Brain‌ ‌MRI‌ ‌demonstrated‌ ‌internal‌ ‌auditory‌ ‌canal‌ ‌enhancement‌ ‌in‌ ‌four ‌patients.‌ Audiometry commonly revealed severe-profound bilateral sensorineural hearing loss. Most patients ‌had‌ a refractory course ‌despite‌ ‌immunotherapy‌ ‌and/or‌ ‌cancer‌ ‌treatment‌. Conclusion Cochleovestibulopathy commonly presents with rapidly progressive bilateral hearing loss and/or acute vertigo. However, in some patients, these symptoms present along with or following brainstem/cerebellar manifestations. KLHL11-IgG and seminoma are the most common serological and cancer associations, respectively. Recognition of this phenotype may aid in earlier diagnosis of paraneoplastic autoimmunity and associated cancer.